Last Updated: 18/06/2024
Understanding high-level resistance to antimalarial PfATP4 inhibitors
Objectives
Thus project seeks to understand the cause and features of this high level resistance in order to assess the magnitude of the threat it poses and devise risk mitigation strategies.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
Recent years have seen new, urgently-needed malaria medicines enter the clinical development pipeline. One new medicine that has performed very well in clinical studies is cipargamin. Unfortunately, it has been shown that malaria parasites grown in the laboratory are capable of acquiring a high level of resistance to this medicine.
External reference
Themes
Date
Jan 2019 — Dec 2020
Total Project Funding
$223,253
Funding Details
National Health and Medical Research Council (NHMRC) Australia, Australia
Grant ID: 1159648
AUD 321,180
Project Site
Related Resources
